Piper Sandler Maintains Neutral on Quest Diagnostics, Raises Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg maintains a Neutral rating on Quest Diagnostics (NYSE:DGX) and raises the price target from $130 to $140.
November 06, 2023 | 3:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler has maintained a Neutral rating on Quest Diagnostics and raised the price target from $130 to $140.
The news directly pertains to Quest Diagnostics (DGX). Piper Sandler's decision to maintain a Neutral rating indicates that they do not expect significant price movement in the short term. However, the increase in price target from $130 to $140 suggests a positive outlook in the longer term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100